Exercise News and Research

Latest Exercise News and Research

Genvec to sell 8,000,000 shares to develop its TNFerade clinical program

GenVec, Inc. (Nasdaq: GNVC) announced today that it has entered into a purchase agreement with a single institutional investor for the sale of 8,000,000 shares of its common stock and warrants to purchase 4,000,000 shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and 0.50 warrants to purchase one share of common stock at a price of $0.75 per unit. This represents a discount of approximately 8.3% to the closing price of GenVec common stock on August 26, 2009. The warrants have a term of five years and an exercise price of $0.828 per share.

28 Aug 2009

Thrombogenics issues business update and half year results

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

28 Aug 2009

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

28 Aug 2009

The Research Partnership study reveals that diabetes can have a major effect on people's lives

A new research study carried out by The Research Partnership reveals that living with diabetes can have a major effect on people's lives, with just under half (44%) of type 2 patients reporting that the condition has impacted on either their ability or their desire to have sex.

28 Aug 2009

NIH panel releases report on the pertinence of family health history information in improving health

Though most Americans are familiar with completing a questionnaire about their family health history when visiting health care providers, an independent panel was convened by the National Institutes of Health this week to critically assess exactly what we know and what we need to learn about how this process relates to improving health.

28 Aug 2009

Alimera Sciences' $5 million extension of Series C financing closed

Alimera Sciences, Inc., today announced that it has closed a $5 million extension of its Series C financing which was originally completed in March 2008.

28 Aug 2009

AAPS and CURE file a free speech lawsuit against the White House

The Office of the President and other White House officials are defendants in a free speech lawsuit filed by a prominent physician group, and a non-profit advocate for inner-city poor.

28 Aug 2009

New risk index for COPD developed to estimate the risk of death

Researchers from the Centre for Research in Environmental Epidemiology (CREAL) and the Municipal Institute of Medical Research (IMIM-Hospital del Mar), in collaboration with the Hospital Clínic of Barcelona, have participated in an international consortium that has developed a new risk index for COPD patients. With this index, doctors can assess disease severity more objectively and estimate the risk of death.

28 Aug 2009

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the dosing of the first patient in a Phase I clinical study of AR-12 (formerly OSU-03012) in adult patients with advanced or recurrent solid tumors or lymphoma.

28 Aug 2009

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced second quarter 2009 financial results.

27 Aug 2009

Department of Veterans Affairs cancels contract with UTSWMC for Gulf War research

Citing persistent noncompliance and numerous performance deficiencies, the Department of Veterans Affairs (VA) will not exercise the third year of a five-year, $75 million contract with the University of Texas Southwestern Medical Center (UTSWMC) to perform research into Gulf War Veterans' Illnesses (GWVI).

27 Aug 2009

Alexza completes acquisition of Symphony Allegro after sharholders' approval

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that during a special meeting of stockholders held today, its stockholders approved the proposal to issue shares of the Company's common stock and warrants to purchase shares of the Company's common stock to Symphony Capital Partners, LP and their co-investors. Subsequent to this vote, Alexza completed its acquisition of Symphony Allegro, and as a result, Alexza reacquired all rights to AZ-004, AZ-104 and AZ-002.

27 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

Novabay Pharmaceuticals closes its previously announced registered direct offering of common stocks and warrants

NovaBay® Pharmaceuticals, Inc. (NYSE Amex: NBY) announced today that it has closed its previously announced registered direct offering of 1,225,000 units, with each unit consisting of (i) one share of the NovaBay common stock, par value $0.01 per share, and (ii) one warrant to purchase one share of NovaBay common stock.

27 Aug 2009

Polycystic ovary syndrome in women can be relieved by acupuncture and exercise

Polycystic ovary syndrome, a common condition among women, can be relieved by the use of acupuncture and exercise. This has been shown by a recent study at the Sahlgrenska Academy, University of Gothenburg, Sweden.

27 Aug 2009

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.

27 Aug 2009

Alegro announces fiscal 2009 second-quarter results

Alegro Health Corp. (TSX-V: AGO), a healthcare services provider, today announced its financial results for the second quarter ended June 30, 2009.

27 Aug 2009

Angeion Corporation announces financial results for third-quarter fiscal 2009

For the 2009 third quarter, Angeion posted a net loss of $173,000, or $0.04 per diluted share, on revenues of $6.2 million. This represents a sequential improvement from a 2009 second-quarter net loss of $225,000, or $0.05 per diluted share, also on revenues of $6.2 million.

27 Aug 2009

Clinical study results of USANA Health Sciences products published in the Obesity and Weight Management journal

USANA Health Sciences, Inc. announced today that results of a large, third-party clinical study involving USANA products, conducted at the University of Colorado Denver (UCD), have been published in the August 2009 edition of the journal Obesity and Weight Management.

26 Aug 2009

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Tikcro Technologies Ltd. (OTC BB: TIKRF) today reported results for the second quarter and six months ended June 30, 2009.

26 Aug 2009

Exercise News and Research

Latest Exercise News and Research

Genvec to sell 8,000,000 shares to develop its TNFerade clinical program

Thrombogenics issues business update and half year results

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

The Research Partnership study reveals that diabetes can have a major effect on people's lives

NIH panel releases report on the pertinence of family health history information in improving health

Alimera Sciences' $5 million extension of Series C financing closed

AAPS and CURE file a free speech lawsuit against the White House

New risk index for COPD developed to estimate the risk of death

Arno Therapeutics to commence Phase 1 clinical study of AR-12 in adult patients with lymphoma

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Department of Veterans Affairs cancels contract with UTSWMC for Gulf War research

Alexza completes acquisition of Symphony Allegro after sharholders' approval

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Novabay Pharmaceuticals closes its previously announced registered direct offering of common stocks and warrants

Polycystic ovary syndrome in women can be relieved by acupuncture and exercise

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Alegro announces fiscal 2009 second-quarter results

Angeion Corporation announces financial results for third-quarter fiscal 2009

Clinical study results of USANA Health Sciences products published in the Obesity and Weight Management journal

Tikcro Technologies announces financial results for the second-quarter ended June 30, 2009

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exercise News and Research

Latest Exercise News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in